Acousys

Search for:

Home
About
Technology
News & Publications
- In the News
- Publications

Improving Health Through Targeting Nuclear Receptors

Sounding the alarm on early melanoma metastasis

“Studies with the Acousys Biodevices system for detection of circulating tumor cells have demonstrated that detection of melanoma cells in the blood of patients with a previous excision of a stage I-III malignant melanoma can predict development of stage IV melanoma. Circulating melanoma cells have been detected in the blood of patients developing metastatic melanoma as much as 8 years in advance of detection of a tumor.”

Dr. John Viator, Ph.D.
Scientific Founder
Acousys Biodevices, Inc.

Acousys Biodevices Inc. is a leader in demonstrating clinical utility of detection of circulating tumor cells (CTCs) to predict recurrence or metastasis of cancer. Recently published data shows the Acousys CTC detection system can identify circulating melanoma cells in patients with stage I-III malignant melanoma up to 8 years in advance of tumor detection (Lasers in Science and Medicine, July 2020). The Acousys system has extraordinary sensitivity, allowing it to detect, and capture rare CTCs for analysis of drug sensitivity. These unique features make the Acousys CTC detection system an ideal tool for monitoring cancer patients for early evidence of disease recurrence, and for personalizing their treatment choices.